Okami Medical Secures $45 Million Funding and Welcomes New CEO to Expand Growth in Medical Technology

Okami Medical's Strategic Growth Initiatives

On November 19, 2025, Okami Medical, a pioneering force in medical technology, declared the successful completion of a $45 million financing round. This funding was overseen by Gilde Healthcare, a new investor, alongside participation from established investors such as Vensana Capital and U.S. Venture Partners. This oversubscribed financing marks a significant milestone in Okami Medical's journey to enhance patient care in the vascular disease arena.

The resources acquired will enable Okami Medical to expand its commercial reach and bolster its clinical programs. The company is dedicated to improving treatment outcomes for patients affected by vascular diseases. The financing will also facilitate further innovation in Okami's range of versatile devices, designed specifically for the occlusion of peripheral vessels, which represents a critical area in medical intervention.

New Leadership to Drive Innovation

In conjunction with this financial boost, Drew Hykes was appointed as the new President and CEO of Okami Medical. Hykes, who previously served as the CEO of Inari Medical, brings a wealth of experience and a strong reputation in the field. In his statement, Hykes expressed his enthusiasm for joining Okami Medical, praising the clinical efficacy and adaptability of the LOBO vascular occluder.

He remarked, “I'm honored to join the Okami team and have been deeply impressed by the clinical performance and versatility of the LOBO vascular occluder across a wide range of anatomies. I look forward to working with this talented team to accelerate our commercial expansion, advance our innovation pipeline, and bring this important technology to more physicians and patients.”

Collaborating with Experienced Partners

As part of the financing arrangements, Geoff Pardo and Susana Amorim from Gilde Healthcare were also appointed to the Board of Directors of Okami Medical. Geoff Pardo, General Partner at Gilde Healthcare, shared their long-standing admiration for Okami’s technology and market potential. He stated, “We have followed Okami for years and have been impressed by the strength of its technology and the scale of its market opportunity.”

This partnership reflects Gilde's commitment to investing in innovative healthcare solutions that address serious unmet needs in the market. The LOBO platform, which focuses on enhancing treatment effectiveness, symbolizes a modern solution tailored to the demanding requirements of today's healthcare landscape.

About Okami Medical

Founded in 2017, Okami Medical operates with the mission to stop flow and restore lives through the development of innovative medical devices for vascular occlusion. The company is dedicated to meeting the evolving needs of patients and healthcare providers. Through cutting-edge research and commitment to quality, Okami aims to revolutionize the approach to vascular treatments, ensuring better outcomes for patients suffering from vascular diseases.

The proactive measures taken by Okami Medical, including this significant financing and new leadership appointments, signal a strong commitment to growth and innovation in the medical technology sector. As they continue to expand, Okami Medical aims to make a substantial impact on the lives of patients and the healthcare system as a whole.

Conclusion

The recent developments at Okami Medical underscore a strategic direction focused on innovation and patient care. With substantial financial backing and leadership changes, Okami is well-positioned to make strides forward in the medical technology industry, reflecting their commitment to transforming vascular treatment methods for better patient outcomes.